China
Africa
Explore chapters and articles related to this topic
Non-Melanoma Skin Cancer
Published in Pat Price, Karol Sikora, Treatment of Cancer, 2020
Irene De Francesco, Sean Whittaker, Stephen L. Morris
There has been considerable debate over the difference between the previous EORTC and WHO classifications of primary cutaneous B-cell lymphoma.174,177 Under the previous EORTC classification, primary cutaneous follicle center cell lymphoma (PCFCCL) defined a group of cutaneous lymphomas highly responsive to RT with an excellent prognosis. The same type of lymphoma with a diffuse growth pattern of large cells was classified under the previous WHO classification as a diffuse large B-cell lymphoma, leading to over-treatment with multi-agent chemotherapy. The other main group debated was primary cutaneous large B-cell lymphoma of the leg (PCLBCL-leg), which was recognized under the EORTC classification as a separate subgroup, reflecting its unfavorable prognosis. Recent clinicopathological and genetic studies support the contention that PCFCCL and PCLBCL-leg are distinct groups, and a consensus was agreed in the WHO-EORTC classification with PCFCCL being defined as primary cutaneous follicle center lymphoma (PCFCL) distinct from nodal follicular lymphoma and PCLBCL-leg as primary cutaneous diffuse large B-cell lymphoma, leg type (see Table 24.2).
Lymphomas and pseudolymphomas
Published in Aimilios Lallas, Enzo Errichetti, Dimitrios Ioannides, Dermoscopy in General Dermatology, 2018
Zoe Apalla, Aimilios Lallas, Enzo Errichetti
Primary cutaneous B-cell lymphomas (PCBCLs) represent about 25% of all PLCs. They are classified into three major categories: primary cutaneous follicle center lymphoma (PCFCL), primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL L-T), and primary cutaneous marginal zone lymphoma (PCMZL).1
Principles of the WHO classification with special reference to aggressive extranodal lymphomas
Published in Franco Cavalli, Harald Stein, Emanuele Zucca, Extranodal Lymphomas, 2008
Harald Stein, Michael Hummel, Lorenz Trümper, Nancy Lee Harris
There are several lymphomas that virtually always present in extranodal sites, and appear to correspond to normal lymphoid cells specific for extranodal immunological reactions (see Table 9.1). Primary extranodal B-cell lymphomas include extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type, primary cutaneous follicle center lymphoma (PCFCL), primary cutaneous diffuse large B-cell lymphoma (DLBCL) of the type commonly found on the lower legs (leg type), plasmablastic lymphoma, primary mediastinal DLBCL (PMBL), primary effusion lymphoma (PEL), intravascular DLBCL, DLBCL associated with chronic inflammation, primary central nervous system DLBCL, and lymphomatoid granulomatosis. Primary extranodal T- and NK-cell lymphomas include hydroa-vacciniforme-like T-cell lymphoma, nasal-type NK/T-cell lymphoma, intestinal (enteropathy-associated) T-cell lymphoma, hepatosplenic T-cell lymphoma, mycosis fungoides, primary cutaneous aggressive CD8+ cytotoxic T-cell lymphoma, primary cutaneous small/medium-sized CD4+ T-cell lymphoma, cutaneous gamma/delta T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, and primary cutaneous anaplastic large-cell lymphoma.
Splenic marginal zone B-cell lymphoma associated with ruptured breast implants: case report and review of the literature
Published in Case Reports in Plastic Surgery and Hand Surgery, 2021
Mark G. Evans, Melissa A. Mueller, Frederik Chen, Larry S. Nichter
The medical literature currently contains twelve cases of B-cell lymphoma occurring in patients with breast implants, including follicular lymphoma, primary cutaneous follicle center lymphoma, intravascular large-cell lymphoma, diffuse large B-cell lymphoma, marginal zone lymphoma, and plasmablastic lymphoma ([1–11], summarized in Table 1). An association between B-cell lymphomas and implants has been previously dismissed given the heterogeneity of such lymphoma cases. However, there are noteworthy commonalities amongst the cases. Many involved textured breast implants that had been compromised. The case presented here is the first case of splenic marginal zone B-cell lymphoma associated with breast implants. While it is unclear whether the ruptured implants directly contributed to the development of lymphoma, silicone granulomas from ruptured implants may have provided an immunologic stimulus. Plastic surgeons should be encouraged to report all cases of lymphoma associated with implants in order to further investigate this relationship.